Genmab — Oktober 2020

[GeorgeBest]

Specielt epco og GEN1046 er ekstremt vigtige da Genmabs ejerandel er 50%

[E_L]

GEN1046 could be the jackpot if it works as good as Jan thinks... but it will still take some time; i don't think the data in november will be able to show us the full potential yet

[GeorgeBest]

Agree

[E_L]

I think Amivantamab is vastly underrated.... JNJ is throwing a lot of effort into it and i think it will be filed sooner as expected -> double royalties at no cost to genmab

[nohope]

Estimated Primary Completion Date : April 30, 2024

[nohope]

Estimated Study Completion Date : November 20, 2025

[E_L]

is that Mariposa? we will not have to wait for that. they have breakthrough therapy designation from the FDA

[E_L]

and...

[E_L]

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT04599712

[nohope]

Ok. Great

[Solsen]

It looks good EL - thanks.

[E_L]

The Phase 1 Talquetamab trial changed into a Phase 1/Phase 2 and increases enrollment from 185 to 245 https://clinicaltrials.gov/ct2/history/NCT03399799?A=20&B=21&C=merged#StudyPageTop

[E_L]

i hope that means the expansion phase is starting? maybe we can get some data at ASH ?

[Helge_LarsenPI-redaktør]

Stoxx: Europæiske health care aktier i plus i stærk negativt
markedhttps://www.proinvestor.com/investornyt/668982/stoxx-europaeiske-health-care-aktier-i-plus-i-staerk-negativt-marked

[Helge_LarsenPI-redaktør]

Ses vi til øl i aften? https://event.webinarjam.com/register/5/qro52t7

[Mogan]

Der er da gang i fukssvansen i dag, men nogen vil have kursen ned, uanset de små opture hen over dagen.

[Solsen]

Det er hele markedet der ryster.

[Mogan]

Enig - og glædes da også over de grønne toppe i aktien vi har set i løbet af dagen, og at vi ligger i den gode ende af de røde tal i C25.

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

God morgen